Reviews on Recent Clinical Trials,
Год журнала:
2023,
Номер
19(1), С. 7 - 33
Опубликована: Ноя. 10, 2023
Cancer
and
infectious
diseases
are
one
of
the
greatest
challenges
modern
medicine.
An
unhealthy
lifestyle,
poor
drug
use,
or
misuse
contribute
to
rise
in
morbidity
mortality
brought
on
by
these
illnesses.
The
inadequacies
medications
now
being
used
treat
disorders,
along
with
growing
issue
resistance,
have
compelled
researchers
look
for
novel
compounds
therapeutic
promise.
number
infections
has
significantly
abated
due
vaccine
development
use
over
time,
which
is
described
detail.
Several
vaccines
can
be
produced
manipulating
Deoxyribonucleic
acid
(DNA),
Ribonucleic
(RNA),
Messenger
(mRNA),
proteins,
viral
vector
Recombinant,
other
molecules
advances
genetic
engineering
our
understanding
immune
defense.
Vaccines,
Год журнала:
2022,
Номер
10(4), С. 591 - 591
Опубликована: Апрель 12, 2022
The
COVID-19
pandemic
has
led
the
world
to
undertake
largest
vaccination
campaign
in
human
history.
In
record
time,
unprecedented
scientific
and
governmental
efforts
have
resulted
acquisition
of
immunizers
utilizing
different
technologies
(nucleotide
acids,
viral
vectors,
inactivated
protein-based
vaccines).
Currently,
33
vaccines
already
been
approved
by
regulatory
agencies
countries,
more
than
10
billion
doses
administered
worldwide.
Despite
undeniable
impact
on
control
pandemic,
recurrent
emergence
new
variants
interest
raised
challenges.
recent
mutations
precede
outbreaks
that
rapidly
spread
at
global
proportions.
addition,
reducing
protective
efficacy
rates
observed
among
main
authorized
vaccines.
Besides
these
issues,
several
other
crucial
issues
for
appropriate
combatting
remain
uncertain
or
under
investigation.
Particularly
noteworthy
include
use
vaccine-boosting
strategies
increase
protection;
concerns
related
long-term
safety
vaccines,
child
immunization
reliability
uncommon
adverse
events;
persistence
virus
society;
transition
from
a
an
endemic
state.
this
review,
we
describe
updated
scenario
regarding
SARS-CoV-2
outline
current
discussions
covering
vaccine
efficacy,
future
perspectives.
Journal of Controlled Release,
Год журнала:
2022,
Номер
353, С. 241 - 253
Опубликована: Ноя. 30, 2022
The
recent
clinical
success
of
multiple
mRNA-based
SARS-CoV-2
vaccines
has
proven
the
potential
RNA
formulated
in
lipid
nanoparticles
(LNPs)
humans,
and
products
based
on
base-modified
RNA,
sequence-optimized
self-replicating
RNAs
LNPs
are
all
various
stages
development.
However,
much
remains
to
be
learned
about
critical
parameters
governing
manufacturing
use
LNP-RNA
formulations.
One
important
issue
that
received
limited
attention
literature
date
is
identification
optimal
storage
conditions
for
preserve
long-term
activity
Here,
we
analyzed
physical
structure,
vivo
expression
characteristics,
functional
alphavirus-derived
(repRNA)-loaded
encoding
HIV
vaccine
antigens
following
varying
temperatures,
buffers,
presence
or
absence
cryoprotectants.
We
found
with
compositions
similar
clinically-used
LNPs,
RNAse-free
PBS
containing
10%
(w/v)
sucrose
at
−20
°C
was
able
maintain
stability
potency
a
level
equivalent
freshly
prepared
30
days
storage.
loaded
repRNA
could
also
lyophilized
retention
bioactivity.
Molecular Therapy,
Год журнала:
2022,
Номер
30(9), С. 2968 - 2983
Опубликована: Апрель 21, 2022
Self-amplifying
RNA
vaccines
may
induce
equivalent
or
more
potent
immune
responses
at
lower
doses
compared
to
non-replicating
mRNA
via
amplified
antigen
expression.
In
this
paper,
we
demonstrate
that
1
μg
of
an
LNP-formulated
dual-antigen
self-amplifying
vaccine
(ZIP1642),
encoding
both
the
S-RBD
and
N
antigen,
elicits
considerably
higher
neutralizing
antibody
titers
against
Wuhan-like
Beta
B.1.351
Delta
B.1.617.2
SARS-CoV-2
variants
those
convalescent
patients.
addition,
ZIP1642
vaccination
in
mice
expanded
S-
N-specific
CD3+CD4+
CD3+CD8+
T
cells
caused
a
Th1
shifted
cytokine
response.
We
induction
such
dual
antigen-targeted
cell-mediated
response
provide
better
protection
displaying
highly
mutated
Spike
proteins,
as
infectious
viral
loads
were
decreased
after
challenge
vaccinated
hamsters.
Supported
by
these
results,
encourage
redirecting
focus
toward
multiple
immunity
addition
bypass
waning
attenuate
breakthrough
disease
severity
future
variants.
Vaccines,
Год журнала:
2022,
Номер
10(2), С. 268 - 268
Опубликована: Фев. 10, 2022
In
the
present
research,
we
focus
on
COVID-19
vaccine
hesitancy,
and
empirically
examine
how
different
forms
of
social
identity
(defensive
vs.
secure
national
identification
with
all
humanity)
conspiracy
beliefs
are
associated
hesitancy.
two
cross-sectional
nationwide
surveys
(Study
1,
Molecular Therapy — Nucleic Acids,
Год журнала:
2023,
Номер
32, С. 794 - 806
Опубликована: Май 9, 2023
The
use
of
modified
nucleosides
is
an
important
approach
to
mitigate
the
intrinsic
immunostimulatory
activity
exogenous
mRNA
and
increase
its
translation
for
therapeutic
applications.
However,
vaccine
applications,
nature
unmodified
could
help
induce
productive
immunity.
Additionally,
ionizable
lipid
nanoparticles
(LNPs)
used
deliver
vaccines
can
possess
properties
that
may
influence
impact
nucleoside
modification.
Here
we
show
uridine
replacement
with
N1-methylpseudouridine
in
encoding
influenza
hemagglutinin
had
a
significant
on
induction
innate
chemokines/cytokines
positive
functional
antibody
titers
mice
macaques
when
MC3
or
KC2
LNPs
were
as
delivery
systems,
while
it
impacted
only
minimally
obtained
L319
LNPs,
indicating
modification
efficacy
varies
LNP
composition.
In
line
previous
observations,
noticed
inverse
correlation
between
high
IFN-α
antigen-specific
immune
responses.
Furthermore,
consistent
species
specificity
pathogen
recognition
receptors,
found
effect
did
not
strictly
translate
from
non-human
primates.
Drug Delivery and Translational Research,
Год журнала:
2024,
Номер
14(6), С. 1725 - 1734
Опубликована: Фев. 10, 2024
Abstract
Antimicrobial
resistance
and
tolerance
(AMR&T)
are
urgent
global
health
concerns,
with
alarmingly
increasing
numbers
of
antimicrobial
drugs
failing
a
corresponding
rise
in
related
deaths.
Several
reasons
for
this
situation
can
be
cited,
such
as
the
misuse
traditional
antibiotics,
massive
use
sanitizing
measures,
overuse
antibiotics
agriculture,
fisheries,
cattle.
AMR&T
management
requires
multifaceted
approach
involving
various
strategies
at
different
levels,
patient’s
awareness
measures
to
reduce
new
resistances,
reduction
current
or
abuse,
improvement
selectivity
treatments.
Also,
identification
including
small
molecules
more
complex
approaches,
is
key
factor.
Among
these,
novel
DNA-
RNA-based
phages,
CRISPR
technologies
some
potent
under
development.
In
perspective
article,
emerging
experienced
leaders
drug
delivery
discuss
most
important
biological
barriers
reach
infectious
bacteria
(bacterial
bioavailability).
They
explore
how
overcoming
these
crucial
producing
desired
effects
ways
which
systems
facilitate
process.
Graphical
abstract
Deleted Journal,
Год журнала:
2025,
Номер
2, С. 1 - 1
Опубликована: Янв. 17, 2025
Messenger
RNA
(mRNA)
technology
has
revolutionized
modern
medicine,
particularly
in
developing
vaccines
and
gene
therapies.
While
its
prominence
soared
during
the
COVID-19
pandemic,
foundation
was
built
on
decades
of
meticulous
research.
This
review
explores
historical
evolution
mRNA
technology,
stabilization
delivery
breakthroughs,
applications
combating
infectious
diseases,
cancer,
genetic
disorders.
The
study
utilized
a
systematic
search
peer-reviewed
articles
from
leading
databases
such
as
PubMed
Scopus,
focusing
advancements
clinical
applications.
Future
potential
treating
chronic
enhancing
immunotherapy,
addressing
public
health
emergencies
is
also
discussed,
emphasizing
need
for
sustained
research
innovation
to
harness
transformative
capabilities
fully.
Expert Review of Vaccines,
Год журнала:
2022,
Номер
21(11), С. 1541 - 1553
Опубликована: Авг. 30, 2022
In
the
first
months
of
novel
coronavirus
(COVID-19)
pandemic
that
begun
in
2020,
non-pharmaceutical
interventions
(NPIs)
have
been
adopted
worldwide.
However,
effects
NPI
implementation
go
beyond
slowing
spread
COVID-19.
Here,
we
review
non-intended
may
arisen
from
prolonged
application
NPIs.NPIs
also
affected
epidemiology
other
infectious
diseases,
with
unprecedentedly
low
circulation
several
respiratory
and
gastrointestinal
viruses
being
observed
worldwide
2020.
While
this
was
a
welcome
effect
for
already
strained
health-care
systems,
exposure
to
pathogens
result
an
increased
pool
individuals
susceptible
certain
diseases.
Out-of-season
or
unusually
intense
outbreaks
non-vaccine
preventable
diseases
documented
as
NPIs
were
gradually
eased.
context
widespread
important
disruptions
national
vaccination
programs
during
early
phase
pandemic,
risk
vaccine-preventable
disease
resurgence
after
are
lifted
cannot
be
excluded
either.Awareness
must
raised
resurgence,
efforts
need
made
mitigate
risk,
where
possible,
by
increasing
coverage.
Research
regulatory
opportunities
brought
on
COVID-19
should
seized.In
only
methods
available
slow
interventions,
such
lockdowns,
mask
wearing,
social
distancing,
school
closures,
travel
bans.
Even
vaccines
against
became
available,
combinations
continued
implemented
most
countries,
various
extents.
Although
these
measures
lowered
number
people
who
got
sick
before
therapies
they
had
consequences
public
health.
The
slowed
even
stopped
diseases:
since
fewer
cases
flu,
bronchiolitis,
gastroenteritis,
recorded
compared
pre-pandemic
times.
This
relatively
long
2-year
period
which
people,
especially
children,
exposed
infections
might
mean
their
immune
systems
less
prepared
fight
addition,
than
dropped
meaning
children
adults
not
protected
has
potentially
increased.
Easing
restrictions
caused
comeback
some
no
vaccine
is
sometimes
more
years;
there
happen
well.
To
prevent
outbreaks,
routine
catch-up
vaccinations
besides
encouraged
promoted.
Vaccines,
Год журнала:
2022,
Номер
10(2), С. 308 - 308
Опубликована: Фев. 16, 2022
More
than
eight
billion
doses
of
COVID-19
vaccines
have
been
administered
globally
so
far
and
44.29%
people
are
fully
vaccinated.
Pre-authorization
clinical
trials
were
carried
out
the
safety
is
still
continuously
monitored
through
post-commercialization
surveillance.
However,
some
afraid
vaccine
side
effects,
claiming
they
could
lead
to
death,
hesitate
get
Herein,
a
literature
review
COVID-19-vaccine-related
deaths
has
according
PRISMA
standards
understand
if
there
causal
relationship
between
vaccination
death
highlight
real
extent
such
events.
There
55
cases
after
reported
excluded
in
17
cases.
In
remaining
cases,
link
was
not
specified
(8)
or
considered
possible
(15),
probable
(1),
very
probable/demonstrated
(14).
The
causes
among
these
were:
vaccine-induced
immune
thrombotic
thrombocytopenia
(VITT)
(32),
myocarditis
(3),
ADEM
myocardial
infarction
rhabdomyolysis
(1).
demonstration
obvious,
more
studies,
especially
with
post-mortem
investigations,
needed
deepen
understanding
pathophysiological
mechanisms
fatal
effects.
any
event,
given
scarcity
benefits
outweigh
risks
scientific
community
needs
be
cohesive
asserting
that
fundamental
containing
spread
SARS-CoV-2.
Cellular & Molecular Biology Letters,
Год журнала:
2022,
Номер
27(1)
Опубликована: Май 13, 2022
Designing
and
producing
an
effective
vaccine
is
the
best
possible
way
to
reduce
burden
spread
of
a
disease.
During
coronavirus
disease
2019
(COVID-19)
pandemic,
many
large
pharmaceutical
biotechnology
companies
invested
great
deal
time
money
in
trying
control
combat
In
this
regard,
due
urgent
need,
vaccines
are
now
available
earlier
than
scheduled.
Based
on
their
manufacturing
technology,
for
COVID-19
(severe
acute
respiratory
syndrome
2
(SAR-CoV2))
infection
can
be
classified
into
four
platforms:
RNA
vaccines,
adenovirus
vector
subunit
(protein-based)
inactivated
virus
vaccines.
Moreover,
various
drugs
have
been
deemed
negatively
affect
progression
via
actions.
However,
adaptive
variants
SARS-CoV-2
genome
alter
pathogenic
potential
increase
difficulty
both
drug
development.
review,
along
with
used
treatment,
currently
authorized
as
well
described
evaluated,
considering
all
platforms.